1180743-50-3

Basic information

• Product Name: [3-[(4-methoxybenzyl)oxy]-4-chlorophenyl]boronic acid
• Synonyms: [3-[(4-methoxybenzyl)oxy]-4-chlorophenyl]boronic acid
• CAS NO: 1180743-50-3
• Molecular Weight: 292.527
• Mol File: 1180743-50-3.mol

Chemical Properties

• CAS DataBase Reference: [3-[(4-methoxybenzyl)oxy]-4-chlorophenyl]boronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: [3-[(4-methoxybenzyl)oxy]-4-chlorophenyl]boronic acid(1180743-50-3)
• EPA Substance Registry System: [3-[(4-methoxybenzyl)oxy]-4-chlorophenyl]boronic acid(1180743-50-3)

Safety Data

• Hazardous Substances Data: 1180743-50-3(Hazardous Substances Data)

Upstream product

• 5419-55-6 Triisopropyl borate 
• 1180743-49-0 2-[(4-methoxybenzyl)oxy]-1-chloro-4-iodobenzene 

Downstream Products

• 956034-27-8 2-[4-chloro-3-(4-methoxy-benzyloxy)-phenyl]-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane 
• 1180743-51-4 methyl 6-[3-[(4-methoxybenzyl)oxy]-4-chlorophenyl]-5-hydroxypyridine-2-carboxylate 

Relevant articles and documents

5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS

The present invention relates to 5,6-bisaryl-2-pyridinecarboxamides, to their preparation and to their therapeutic use as urotensin II receptor antagonists.

Pharmaceutical compounds

Compounds of Formulae Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.